A2T Stock Overview
A biomedical company, provides diagnostic services and medical treatments.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Atrys Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.97 |
| 52 Week High | €5.66 |
| 52 Week Low | €2.45 |
| Beta | 0.41 |
| 1 Month Change | 41.79% |
| 3 Month Change | 36.43% |
| 1 Year Change | -19.31% |
| 3 Year Change | -52.05% |
| 5 Year Change | n/a |
| Change since IPO | -56.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| A2T | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 16.8% | -1.4% | -0.3% |
| 1Y | -19.3% | -0.9% | 4.5% |
Return vs Industry: A2T underperformed the German Healthcare industry which returned -0.9% over the past year.
Return vs Market: A2T underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| A2T volatility | |
|---|---|
| A2T Average Weekly Movement | 8.3% |
| Healthcare Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: A2T's share price has been volatile over the past 3 months.
Volatility Over Time: A2T's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,865 | Isabel Lozano Fernandez | www.atryshealth.com |
Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
Atrys Health, S.A. Fundamentals Summary
| A2T fundamental statistics | |
|---|---|
| Market cap | €317.41m |
| Earnings (TTM) | -€30.45m |
| Revenue (TTM) | €206.10m |
1.5x
P/S Ratio-10.4x
P/E RatioIs A2T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A2T income statement (TTM) | |
|---|---|
| Revenue | €206.10m |
| Cost of Revenue | €148.96m |
| Gross Profit | €57.15m |
| Other Expenses | €87.59m |
| Earnings | -€30.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 27.73% |
| Net Profit Margin | -14.77% |
| Debt/Equity Ratio | 76.1% |
How did A2T perform over the long term?
See historical performance and comparison